Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomized phase III trials

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomized phase III trials

Author Caseiro, Marcos M. Google Scholar
Nelson, Mark Google Scholar
Diaz, Ricardo S. Autor UNIFESP Google Scholar
Gathe, Joseph Google Scholar
Andrade Neto, Jose L. de Google Scholar
Slim, Jihad Google Scholar
Solano, Antonio Google Scholar
Netto, Eduardo M. Google Scholar
Mak, Carmen Google Scholar
Shen, Junwa Google Scholar
Greaves, Wayne Google Scholar
Dunkle, Lisa M. Google Scholar
Vilchez, Regis A. Google Scholar
Zeinecker, Jennifer Google Scholar
VICTOR-E3 Grp Google Scholar
Victor-E4 Study Grp Google Scholar
Institution Hosp Guilherme Alvaro
Chelsea & Westminster Hosp
Universidade Federal de São Paulo (UNIFESP)
Therapeut Concepts
Pontificia Univ Catolica Parana
St Michaels Hosp
Hosp Calderon Guardia
Merck Sharp & Dohme Corp
Desmond Tutu HIV Fdn
Abstract Background: Vicriviroc, a novel HIV CCR5 antagonist, demonstrated significant efficacy and favorable tolerability in phase II trials in treatment-experienced subjects, supporting further evaluation in phase III studies.Methods: Two identical double-blind, placebo (PBO)-controlled trials in CCR5-tropic HIV-infected subjects with documented resistance to two antiretroviral classes were conducted. Subjects were randomized to vicriviroc 30 mg QD (N = 571) or PBO (N = 286) with open-label optimized background therapy (OBT) containing >= 2 fully active antiretroviral drugs. the primary endpoint was percentage of subjects with <50 copies/mL HIV RNA at 48 weeks. It was analyzed in a logistic regression with treatment (vicriviroc+OBT/PBO+OBT), use of enfuvirtide in baseline OBT (yes/no), and baseline HIV RNA (<= 100,000/>100,000 copies/mL) as covariates. in addition, a pre-planned analysis to examine other efficacy and safety endpoints was conducted.Results: Baseline characteristics of the pooled mITT population (vicriviroc, n = 486; PBO, n = 235) included mean HIV RNA of 4.6 log(10) copies/mL and mean CD4 count of 257 cells/mu L. Approximately 60% of subjects received >= 3 active drugs in the OBT. the percentage of subjects with <50 copies/mL HIV RNA was not significantly different between vicriviroc and PBO at week 48 (64% vs 62%, p = 0.6). However, in subjects receiving <= 2 active drugs in their OBT, the proportion achieving <50 copies/mL HIV RNA was higher in those receiving vicriviroc compared with PBO (70% vs 55%, p = 0.02).Conclusions: the studies failed to show significant efficacy gains when vicriviroc was added to OBT. However, given the efficacy results of earlier vicriviroc trials and other CCR5 antagonist, studies are needed to define the role of this class of drugs in the treatment of HIV.
Keywords CCR5 antagonist
Vicriviroc
HIV-1
Treatment-experienced patients
Language English
Sponsor Schering-Plough Corp., Merck Sharp Dohme Corp.
Merck & Co., Inc., Whitehouse Station, NJ, USA
Date 2012-10-01
Published in Journal of Infection. London: W B Saunders Co Ltd, v. 65, n. 4, p. 326-335, 2012.
ISSN 0163-4453 (Sherpa/Romeo, impact factor)
Publisher W B Saunders Co Ltd
Extent 326-335
Origin http://dx.doi.org/10.1016/j.jinf.2012.05.008
Access rights Closed access
Type Article
Web of Science ID WOS:000308727100006
URI http://repositorio.unifesp.br/handle/11600/35373

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account